Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Axsome Therapeutics's Esreboxetine?
Esreboxetine is a small molecule commercialized by Axsome Therapeutics, with a leading Phase III program in Fibromyalgia (Fibromyalgia Syndrome). According...
Data Insights
Risk adjusted net present value: What is the current valuation of Axsome Therapeutics's Esreboxetine?
Esreboxetine is a small molecule commercialized by Axsome Therapeutics, with a leading Phase III program in Fibromyalgia (Fibromyalgia Syndrome). According...